Breast Cancer

Latest News


CME Content


The demand for genetic services has never been greater. Vast advances in genetic technology, Angelina Jolie's disclosure that she is a BRCA mutation carrier, and the Supreme Court ruling on gene patents have hurled genetic services into the mainstream. Since the Supreme Court ruling last year, the cost of germline (hereditary) genetic testing has plummeted and now includes panels of genes.

A randomized multi-center trial examining the efficacy of adding the prohormone dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women, and that when DHEA is added, survivors report significant improvements in sexual desire, arousal, pain, and overall sexual function.

Researchers at The University of Texas at Austin have found that postmenopausal overweight or obese breast cancer patients receiving hormone therapy as part of their treatment who use nonsteroidal anti-inflammatory drugs (NSAIDs) have significantly lower breast cancer recurrence rates and a sizable delay in time to cancer recurrence.

Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene, according to a study published in The New England Journal of Medicine (NEJM).

A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has shown that electroacupuncture produces significant improvements in fatigue, anxiety, and depression in as little as 8 weeks for early-stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs).